Inactive

CDC Office of Acquisition Services awarded multiple indefinite delivery, indefinite quantity (IDIQ) contracts for the National Center for Immunization and Respiratory Diseases (NCIRD) for the purchase... CDC Office of Acquisition Services awarded multiple indefinite delivery, indefinite quantity (IDIQ) contracts for the National Center for Immunization and Respiratory Diseases (NCIRD) for the purchase of standard commercial pediatric & adult vaccines, manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration (FDA). The vaccines awarded under these contracts will be purchased for NCIRD’s immunization awardees (the fifty state health departments, several large city program and current and former U.S. Territories) to support immunization programs as provided under Section 317(j) of the Public Health Service Act and VFC, as established pursuant to Section 13631 of the Omnibus Budget Reconciliation Act of 1993. The initial pediatric contracts, awarded in April 2025 were established to support public sector ACIP recommended routine vaccinations for children. Merck’s pediatric contract will be modified to support purchase of Clesrovimab (Enflonsia), which is indicated for the prevention of RSV lower respiratory tract disease, hospitalization, and death in neonates and infants who are born during or entering their first RSV season, in light of the ACIP approval and accompanying VFC resolution on June 25, 2025. Clesrovimab from Merck is the second product currently licensed for the prevention of RSV in neonates and infants to prevent severe RSV disease. CDC’s current pediatric contract with Merck will be modified to include ~750,000 doses required to support purchase of Clesrovimab to administer to VFC eligible neonates and newborns. CDC intends on awarding a sole source follow on action to Merck to allow for the addition of Clesrovimab. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.